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Novel Withanolide chemical genetic probes identify the in 
vivo binding target of withaferin A, which is the intermediate 
?lament type III protein vimentin. In addition, a Withanolide 
based small molecule screening method screens drug candi 
dates that target intermediate ?lament type III proteins. The 
method includes introducing a tagged linker covalently 
bonded to the Withanolide molecule to form a Withanolide 
probe. Better or alternative small molecule compounds as 
potential drug candidates can be generated based on their 
likely af?nity for the determined binding site in vimentin. The 
ai?nity labeled Withanolide can also be used to ?nd interme 
diate ?lament-associated proteins using chemical proteomics 
by extracting proteins from cells that were exposed to Witha 
nolide-biotin analog. The Withanolide probes can be used to 
monitor expression of vimentin, in tumor samples or other 
diseased tissues. Withaferin analogs can be used as a treat 
ment for diverse vimentin-associated disorders, such as can 
cers, angio?brotic diseases, and chronic in?ammation. 
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WITHANOLIDES, PROBES AND BINDING 
TARGETS AND METHODS OF USE 
THEREOF 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This patent claims priority to US. provisional patent appli 
cation Ser. No. 60/785,972, ?led Mar. 27, 2006, herein incor 
porated by reference. 
FIELD OF THE INVENTION 
The present invention relates to compounds for targeting 
human or animal disease states characterized by aberrant 
expression of the intermediate ?lament type III proteins, such 
as vimentin, methods and compounds for detecting interme 
diate ?lament type III proteins, such as vimentin, and com 
pounds for use in screening small molecules that target inter 
mediate ?lament proteins. 
BACKGROUND OF THE INVENTION 
Natural products that demonstrate pharmacological e?i 
cacy are very important chemical scaffolds for drug design. 
While the vast majority of small molecule natural products 
will eventually be screened for biological activity, only a 
small fraction of these drug-like agents will move forward in 
the drug development pipeline. Currently, a considerable 
amount of effort is being directed through high throughput 
screening to select lead candidates based on their ability to 
bind to validated disease-associated protein targets. 
A new approach has emerged that employs biologically 
active small molecules as cell permeable probes to identify 
novel binding targets and to study their function. Since phar 
macological activity of a small molecule resides principally 
through binding interaction with its hypothetical biological 
target(s) (e.g., protein receptor), it is the discovery of such a 
protein receptor is of critical importance in drug develop 
ment. Furthermore, the identi?cation of the speci?c amino 
acid of the protein target to which the small molecule binds 
offers molecular insight into the speci?city of such binding 
interactions. Consequently, the use of the binding site infor 
mation allows one to look for similar binding sites in other 
classes of proteins, molecular information that helps expand 
the target cell types/organisms and clinical indications for the 
small molecule drug lead. The discovery of VIAGRATM for 
male sexual dysfunction is one such example where research 
on phoshodiesterase inhibitors for cardiovascular dysfunc 
tion led to the serendipitous identi?cation of a novel thera 
peutic area for this class of drugs. 
In small molecule protein target discovery research, the 
most critical element is the innovative chemical design to 
convert a drug-like chemical compound into a useful biologi 
cally active chemical probe that affords the ability to use the 
reagent for identi?cation of its in vivo protein binding target. 
Careful consideration is paid to not alter any of the small 
molecule’s biological activities when the synthetic analog is 
generated. In addition, it is also important that a level of 
speci?city for protein binding is demonstrated. Chemical 
radioisotope tagging is commonly used to generate a radio 
labeled analog of the small molecule to help in protein target 
detection. However, a major drawback with this approach is 
that this method does not afford a direct means to isolate the 
binding target of this agent. 
One recent screening method uses a?inity tagging small 












seemingly provides the potential for isolating a small mol 
ecule binding target. Unfortunately, current techniques of 
biotin a?inity tagging have not realized the full potential of 
isolating the binding target for small molecule agents due, in 
part, to the presence of the biotin attached to the small mol 
ecule, which may interfere with the natural binding of the 
small molecule analog with its target. 
One small molecule is the natural product Withaferin A 
(hereinafter “WF ”), which is a potent angiogenesis inhibitor 
that targets the ubiquitin-proteasome pathway in vascular 
endothelial cells. WFA is an important prototype of the witha 
nolide class of natural products and is a highly oxygenated 
steroidal lactone that is found in the medicinal plant Wilhani a 
somnifera and its related solanaceas species. The withano 
lides are known to exert very potent and diverse cytotoxic, 
anti-stress, cardioactive, central nervous system, and immu 
nomodulatory activities. Since the early discovery of WFA 
during the 1960s, the major interest has been on its anti-tumor 
cytotoxic activities. The mesenchymal type-III intermediate 
?lament (“IF”) protein vimentin plays a critical role in wound 
healing, angiogenesis and cancer growth. 
The role of vimentin in human and animal disorders, 
including those disorders associated with aberrant or elevated 
expression of vimentin, and diseases associated with angio 
genesis are known in the prior art, e.g. by the following 
references, US. Pat. Nos. 5,716,787; 5,932,545; 6,846,841; 
7,132,245; 7,175,844; US. Patent application publication no. 
2006/0014225; Hertig A, Verine J, Mougenot B, Jouanneau 
C, Ouali N, Sebe P, GlotZ D, Ancel P Y, Rondeau E, Xu 
Dubois Y C; Risk factors for early epithelial to mesenchymal 
transition in renal grafts, Am J Transplant; 2006 December; 
6(12):2937-46 (hereinafter “Hertig et al.”); Kenyon, B. M., et 
al., “Effects of Thalidomide and Related Metabolites in a 
Mouse Corneal Model of Neovascularization”, Exp. Eye 
Res., 64:971-978 (1997) (hereinafter “Kenyon et al.”); Cole, 
C. H., et al., “Thalidomide in the management of chronic 
graft-versus-host disease in children following bone marrow 
transplantation”, Bone Marrow Transplantation, 14:937-942 
(1994) (hereinafter “Cole et al.”); Russell, M. E., et al., 
“Chronic Cardiac Rejection in the LEW to F344 Rat Model”, 
J. Clin. Invest., 97(3):833-838 (1996) (hereinafter “Russell et 
al.”; KwonY S, Kim J C. Inhibition of corneal neovascular 
ization by rapamycin, Exp Mol Med. 2006 Apr. 30; 38(2): 
173-9 (hereinafter “Kwon et al.”); Zogakis T G, Libutti S K, 
General aspects of anti-angiogenesis and cancer therapy, 
Expert Opin Biol Ther, 2001 March; 1(2):253-75, Review; 
Kirsch M, Santarius T, Black P M, Schackert G, Therapeutic 
anti-angiogenesis for malignant brain tumors. Onkologie, 
2001 October; 24(5):423 -30. Review hereinafter “Zogakis et 
al.”); Manzano R, Peyman G, Khan P, Carvounis P, Kivilcim 
M, Ren M, Lake I, CheveZ-Barrios P, Inhibition of experi 
mental corneal neovascularization by Bevacizumab(AVAS 
TIN), Br] Opthalmol. 2006 Dec. 19 (hereinafter“Manzano et 
al.”); Yeh J R, Mohan R, Crews C M, The antiangiogenic 
agent TNP-470 requires p53 and p21 CIP/WAF for endothe 
lial cell growth arrest, Proc Natl Acad Sci USA. 2000 Nov. 7; 
97(23):12782-7 (hereinafter “Yeh et al.”);YuY, Moulton K S, 
Khan M K, Vineberg S, Boye E, Davis V M, O’Donnell P E, 
Bischoff J, Milstone D S, E-selectin is required for the anti 
angiogenic activity of endostatin, Proc Natl Acad Sci U S A. 
2004 May 25; 101(21):8005-10 (hereinafter “Yu et al.”); 
Murthy R C, McFarland T J, Yoken J, Chen S, Barone C, 
Burke D, Zhang Y, Appukuttan B, Stout J T, Corneal trans 
duction to inhibit angiogenesis and graft failure, Invest 
Opthalmol V is Sci. 2003 May; 44(5):1837-42 (hereinafter 
Murthy et al.”); Rogers M S, Rohan R M, Birsner A E, 
D’Amato R J. Genetic loci that control the angiogenic 
US 8,735,178 B2 
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response to basic ?broblast growth factor. FASEB J. 2004 
July; 18(10)11050-9 (hereinafter “Rogers et a1.”); Zhang M, 
Volpert O, Shi Y H, Bouck N. Maspin is an angiogenesis 
inhibitor, Nat. Med. 2000 February; 6(2):l96-9 (hereinafter 
“Zhang et a1.”); and Mor-Vaknin N, Punturieri A, Sitwala K, 
Markovitz D M, Vimentin is secreted by activated macroph 
ages, Nat Cell Biol. 2003 January; 5(1):59-63 (hereinafter 
“Mor-Vaknin et a1.”); all herein incorporated by reference. 
Although the role of vimentin, and diseases associated with 
angiogenesis are known in the prior art, the non-cytotoxic 
anti-in?ammatory and immunomodulatory mechanisms of 
WFA have thus far remained rather poorly characterized. 
These latter disease-altering activities are highly pertinent to 
the practice of ayurveda, a traditional form of Indian medi 
cine, which has borne out many effective formulations from 
W somnifera, especially for the treatment of chronic human 
diseases such as arthritis and female bleeding disorders. 
SUMMARY OF THE INVENTION 
The present invention relates to compounds for targeting 
functions of intermediate ?lament type III proteins, in par 
ticular, vimentin. The ability of certain withanolides to bind 
vimentin is positively correlated to the anti-angiogenic and 
anti-in?ammatory activity of this compound class. 
The present invention also relates to compounds and meth 
ods for detecting intermediate ?lament type III proteins, such 
as vimentin. For example, withanolide derivatives with 
chemical or radioactive tags can be used as detection probes 
and/or assist with the isolation of withanolide binding pro 
teins and target-associated co-isolated proteins. 
The present invention also relates to a method for screening 
small molecules as potential drug candidates that interfere 
with binding of WFA to its target protein binding site by use 
of a tagged withanolide analog, as demonstrated with bioti 
nylated WFA. For example, a withanolide analog can be used 
to screen drugs that target intermediate ?lament proteins. In 
one form, the af?nity tag biotin, which is covalently bonded to 
a hydrocarbon linker having a chain of C l-C20 (of structures 
shown) covalently bonded to the withanolide. 
Affinity tagging with biotin allows for both the detection of 
the target protein of the small molecule and the target sites by 
isolation of the small molecule-bound protein target using 
af?nity chromatography. The isolation of the target bound to 
the small molecule analog allows for the determination of the 
binding site. From knowing the target binding site, one can 
generate and develop tailored new classes of small molecule 
compounds, which may be even better drug candidates than 
the parental molecule. 
Two key aspects, which allow for the isolation of the small 
molecule analog bound to its target, are that the placement of 
the biotin moiety should not hinder the small molecule’s 
pharmacophores and that the small molecule biotin adduct 
must be separated by a chemical linker long enough that it 
allows the small molecule to enter into living cells and bind to 
its target in vivo. 
A highly validated approach was used to test the effective 
ness of the present screening method using small molecule 
analogs labeled with an af?nity tag by designing a WFA 
biotin af?nity reagent as a test small molecule analog. The 
WFA-biotin af?nity reagent utilized previous known struc 
ture-activity relationship studies to determine the pharma 
cophores of WFA. This information was used to generate a 
novel cell-permeable af?nity analog of WFA that retains bio 











disclosed by Yokota et al., Development of Withaferin A., 
Bioorg Med Chem Lett. (2006), herein incorporated by ref 
erence. 
A small molecule screening method comprises generating 
an af?nity labeled withanolide analog by binding withanolide 
compound to an af?nity tag via a linker group; introducing the 
af?nity labeled withanolide analog to a cell culture that has 
been exposed to small molecule drug candidates; and con 
tacting the af?nity labeled withanolide analog with one of: (i) 
a puri?ed protein that has been exposed to one or more small 
molecule drug candidates; (ii) a cell extract that has been 
exposed to one or more small molecule drug candidates; and 
(iii) a protein mixture that has been exposed to one or more 
small molecule drug candidates. 
Using the present method, a small molecule canbe selected 
as a potential drug based on its binding to the target. In 
addition, the present method can be used to determine a target 
binding site for the small molecule and/or the withanolide 
compound with the target. 
In addition, a second small molecule can be generated 
based on its likely af?nity for the determined target binding 
site, leading to other potential drug candidates. 
The present invention, in another form thereof, relates to a 
method of producing a small molecule probe comprising a 
withanolide compound that has been conjugated to an af?nity 
tag via a linker group. The af?nity tag may be a biotin moiety 
and the linker group may be a C 1 -C20 long hydrocarbon chain 
linker. 
The present invention, in another form thereof, relates to an 
af?nity labeled screening compound analog comprising a 
withanolide covalently bonded to a linker molecule, which is 
itself covalently bonded to an af?nity moiety tag. 
Without being bound to any particular theory, the present 
invention in another form, concerns a method for treating 
diverse human or animal disorders characterized by aberrant 
or elevated levels of vimentin comprising administering an 
effective amount of WFA or a withanolide analog compound 
to an individual or animal in need of treatment therefrom to 
bind to vimentin, thereby treating the disease associated with 
elevated levels of vimentin. The disorders include but are not 
limited to angio?broic diseases such as tumors, macular 
edema, proliferative diabetic retinopathy, macular degenera 
tion, neovascular glaucoma, corneal neovascularization, and 
endometriosis and diseases with scar tissue formation such as 
scleroderma, keloids, kidney ?brosis, pulmonary ?brosis, 
cardiac ?brosis, chemotherapy/radiation induced lung ?bro 
sis, pancreatitis, in?ammatory bowel disease, Crohn’s dis 
ease, hypertrophic scar, nodular fasciitis, eosinophilic fascii 
tis, Dupuytren’s contracture, general ?brosis syndrome, 
characterized by replacement of normal muscle tissue by 
?brous tissue in varying degrees, retroperitoneal ?brosis, 
liver ?brosis, and acute ?brosis, chronic in?ammation such as 
Crohn’s disease, ulcerative colitis, psoriasis, sarcoidosis, and 
rheumatoid arthritis, and organ transplant failure. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1a shows the chemical structures of WFA and l2-D 
WS, 
FIG. 1b is a Coomassie blue stained gel depicting af?nity 
isolation of WFA-B binding proteins, 
FIG. lc is a protein blot depicting WFA-B binding to a 56 
kDa protein in HUVECs, 
FIG. 1d is a protein blot depicting WFA-B binding to 
vimentin in HUVECs, and 
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FIG. 1e is a protein blot depicting tetrameric soluble ham 
ster vimentin incubated with different doses of WFA or inac 
tive congener l2-D WS; 
FIG. 2a is a snapshot of a MD-simulated solvent accessible 
surface area binding structure showing WFA binding in the 
cleft between the A and A' (x-helices of the vimentin tetramer, 
FIG. 2b is an enlargement of a portion of FIG. 2a, showing 
the A-ring twist-boat and B-ring half-chair conformation of 
WFA accommodated deep within the binding cleft of the 
vimentin tetramer, 
FIG. 20 is a ribbon model showing hydrogen bonding 
between Gln324 of the vimentin A-helix and the Cl position 
oxygen atom, and Asp33 l of the vimentin A'-helix and the C4 
hydroxyl group, and 
FIG. 2d depicts the alpha orientations of the C5 (OH) and 
C6-C7 (epoxide) of the inactive withanolide congener l2-D 
WS appose Cys328 of vimentin; 
FIG. 3a depicts tetrameric soluble hamster vimentin poly 
merized in the presence of 170 mM NaCl, 
FIG. 3b depicts polymerization of tetrameric vimentin in 
the presence of 25 uM WFA, 
FIG. 30 depicts irregular fragmented aggregated struc 
tures, 
FIG. 3d shows that l2-D WS does not disrupt vimentin 
polymerization, 
FIGS. 3e-3j are micrographs in which the BAECs are 
treated with DMSO (FIGS. 3e, 3f and 3g) or 3 uM WFA 
(FIGS. 3h, 3i and 3 j) for 18 hours, stained for vimentin using 
a monoclonal anti-vimentin antibody, and co-stained with 
phalloidin-rhodamine, 
FIG. 3k is a western blot analysis of HUVECs showing 
do se-responsive increases in vimentin cleavage products pro 
duced by WFA treatment, and 
FIG. 3l is a western blot depicting higher concentrations 
and longer periods of exposure to WFA cause reduction in 
levels of the 56 kDa protein; 
FIG. 411 comprises an upper panel blot depicting MCF-7 
cells which lack endogenous IF proteins which were trans 
fected with human vimentin cDNA or vector control and after 
24 hour cells treated with either vehicle or 2 uM WFA, 
FIG. 4b is a plot showing 208 proteasome preparation 
incubated with vehicle, Epoxomicin or WFA in the presence 
of LLVY-AMC substrate, 
FIG. 40 is a graph of embryonic ?broblast cell lines derived 
from vimentin-de?cient mice and wild-type littermates 
treated with vehicle or 5 uM WFA, 
FIG. 4d is a micrograph showing BAECs transduced with 
WFA-modi?ed vimentin and cells stained for vimentin, 
FIG. 4e is a micrograph depicting BAECs transduced with 
WFA-modi?ed vimentin and stained for actin, 
FIG. 4f is a micrograph depicting BAECs transduced with 
vehicle-treated vimentin having well distributed orchestra 
tion of vimentin ?laments, and 
FIG. 4g depicts BAECs transduced with vehicle-treated 
vimentin having well distributed orchestration of actin 
cytoskeleton; and 
FIG. 511 comprises four panels of various micrographs in 
which wild-type mice and vimentin-de?cient mice were sub 
jected to corneal chemical injury, and 
FIG. 5b are plots quantifying neovascularization from each 
group of mice from FIG. 5a. 
DETAILED DESCRIPTION 
A novel withanolide chemical genetic probe is used to 
identify, in vivo, the binding target of withaferin A, which is 
the intermediate ?lament type III protein vimentin. For 
example, a withanolide-based small molecule is used in a 
screening method to screen drug candidates that target inter 











ducing a tagged linker covalently bonded to the withanolide 
molecule to form a withanolide analog. The linker may be a 
C l-C2O long hydrocarbon chain linker and the af?nity tag can 
be a biotin moiety. 
As a result, the linker spaces the af?nity group suf?ciently 
from the small molecule moiety so as to prevent the af?nity 
tag from interfering with the normal binding of the small 
molecule with its target. Accordingly, the present invention 
allows for a more accurate identi?cation of a small mol 
ecule’s binding site on a target and identi?cation of the target 
binding sites without the af?nity group interfering with the 
binding of the small molecule with the target. 
The af?nity tag and linker are selected so as to not interfere 
with the uptake of the small molecule analog by a target cell. 
The exact composition or form of the linker group is not 
particularly relevant so long as the linker group suf?ciently 
spaces the af?nity group from the small molecule and the 
linker group does not adversely effect the binding of the small 
molecule with its target. The af?nity tag can be biotin or any 
other appropriate af?nity tag which can be covalently bound 
to the linker. 
Better or alternative potential small molecule compounds 
as potential drug candidates can be generated based on their 
likely af?nity for the determined binding site. 
The af?nity labeled withanolide can also be used to ?nd 
intermediate ?lament-associated proteins via chemical pro 
teomics by extracting proteins from cells that were exposed to 
withanolide-biotin analog. The withanolide probes can be 
used to monitor expression of vimentin, in tumor samples or 
other diseased tissues. The Withaferin analogs can be used as 
a treatment for vimentin associated cancers, such as epithe 
lial-to-mesenchymal transition found in epithelial cancers, 
such as breast cancer, using WithaferinA and other analogues 
which also target vimentin. The Withaferin analogs also can 
be used as a treatment for other vimentin associated disorders, 
including but not limited to a broad range of angiobibrotic 
diseases with scar tissue formation, chronic in?ammation, 
and organ transplant failure. 
Examples of preferred withanolide analogs include the 
following structures: 




(a) Ra, Rb & Rc are 40H; or 
(b) Ra, Rb and Rc are independently iO-Rd-Re, 
Rd is a straight or branched alkyl With up to 12 carbons or 
aralkyl, 
Re is 40H, iNHZ, 4Cl, Br, *1, iF, CF3, or biotin, 
digoxigenin, BODIFY (8-chloromethyl-4,4-di?uoro-1,3,5, 
7-tetramethyl-4-bora-3a,4a-diaza-s-indacene) succinate, or 










(c) Ra, Rb & Rc are independently 4OiC(:O)-Rd-Re, 
Rd is a straight or branched alkyl With up to 12 carbons or 
aralkyl, 
(i) Re is iOH, iNHZ, iCl, Br, *1, iF, CF3 or biotin, 
digoxigenin, BODIFY (8-chloromethyl-4,4-di?uoro-1, 
3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene) suc 
cinate, or radioactive ligand iO4C(:O)iR-Rd, 
Where R is mono- di- tri-ethyleneglycol; or 
(ii) Re is OH, iNHZ, 4Cl, Br, *1, iF, CF3 or biotin, 
digoxigenin, BODIFY (8-chloromethyl-4,4-di?uoro-1, 
3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene) suc 
cinate, or radioactive ligand; or 
(d) Ra, Rb & Rc are independently 4OiC(:O)iXi 
NHiRe Where X is a straight or branched alkyl With up to 
12 carbons or mono. di- tri-ethyleneglycol, 
Re is 40H, iNHZ, iCl, Br, *1, iF, CF3 or biotin, 
digoxigenin, BODIFY (8-chloromethyl-4,4-di?uoro-1, 
3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene) suc 
cinate, or radioactive ligand or Rd is i(C:O)iRe, 
Re is Cy5.5 acetate, Fluorescein acetate, 2-Naphthoxy 
acetate, Benzoyl, Benzoyl benzyl acetate, phloro-ac 
etophenone acetate, 4-methoxy-2-hydroxy-benzoate, 
Alexa succinate, Coumarin acetate, 1-naphthyl, 1-, or 
1,3- or, 1,3,5-methoxy-benzyl, 1 to 5 ?uoro-benzyl or 
piperazynyl; or 
(e) Ra, Rb & Rc are independently 404C(:O)iXiYi 
Z, Where X is a straight or branched alkyl With up to 12 
carbons or mono- di- tri-ethyleneglycol 
(i)Y is penta, hexa, hepta and octapeptides comprising any 
combination of amino acids selected from the group 
consisting of Leu, Ala, Pro Tyr, lle, hydroxy proline, and 
Cys; and Z is (argine)8, Z;OH, iO-benzyl, iNH2; 
or 
(ii) Y is (argine)8, and erenta, hexa, hepta and octapep 
tides comprising any combination of amino acids selected 
from the group consisting of Leu, Ala, Pro Tyr, lle, hydroxy 
proline, and Cys. 
The preferred dose for administration of a Withanolide 
compound composition in accordance With the present inven 
tion is that amount Which Will be effective in preventing or 
treating a vimentin associated disease such as, but not limited 
to cancers, a broad range of angio?brotic diseases With scar 
tissue formation, chronic in?ammation, and organ transplant 
failure, would readily recognize that this amount Will vary 
greatly depending on the nature of the disorder and the con 
dition of a patient. An “effective amount” of the Withanolide 
compound or pharmaceutical agent to be used in accordance 
With the invention is intended to mean a nontoxic but suf? 
cient amount of the agent, such that the desired prophylactic 
or therapeutic effect is produced. Thus, the exact amount of 
the Withanolide compound or a particular agent that is 
required Will vary from subject to subject, depending on the 
species, age, and general condition of the subject, the severity 
of the condition being treated, the particular carrier or adju 
vant being used and its mode of administration, and the like. 
Similarly, the dosing regimen should also be adjusted to suit 
the individual to Whom the composition is administered and 
Will once again vary With age, weight, metabolism, etc. of the 
individual. Accordingly, the “effective amount” of any par 
ticular Withanolide compound or composition Will vary based 
on the particular circumstances, and an appropriate effective 
amount may be determined in each case of application by one 
of ordinary skill in the art using only routine experimentation. 
It Will be clear to one of ordinary skill in the art, Which 
vimentin associated conditions or diseases Will bene?t from 
the present treatment, based on the role of vimentin in such 
conditions or diseases and the effect the binding of a Witha 
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nolide compound or a particular agent to the vimentin has on 
the role of vimentin. For example, it will be known to one of 
ordinary skill in the art, which angiogenesis diseases, includ 
ing cancers, which will bene?t from the present treatment 
with a withanolide compound or a particular agent in accor 
dance with the present treatment method. 
The present small molecule screening method in which 
small molecule analogs comprising small molecules 
covalently bonded to an af?nity tag via a linker was estab 
lished using various experiments with WFA binding proteins. 
These experiments con?rm that af?nity tagged small mol 
ecules can be used to determine the speci?c binding sites on 
target molecules, such as proteins. From knowing the target 
binding sites, new or additional small molecules can be devel 
oped as potential drug candidates, which have af?nity for the 
target binding site. Thus, the present experiments demon 
strate the effectiveness of a screening method which can be 
used to determine new potential drug candidates which bind 
to those target binding sites. 
For example, as shown by Eckes, B. et al., Impaired wound 
healing in embryonic and adult mice lacking vimentin, J. Cell 
Sci. 113, 2455-2462 (2000); and van Beijnum, J. R. et al., 
Gene expression of tumor angiogenesis dissected: speci?c 
targeting of colon cancer angiogenic vasculature, Blood 108, 
2339-2348 (2006), both herein incorporated by reference, the 
small molecule angiogenesis inhibitor WFA binds to tet 
rameric vimentin by covalently modifying the cysteine resi 






ing on what is know in the art with regard to the role of 
vimentin with regard to disease conditions such as ?brosis 
and in?ammation as discussed in the above background sec 
tion, WFA binding to tetrameric vimentin induces ?lamen 
tous aggregation in vitro, which manifests in vivo as punctu 
ate cytoplasmic aggregates that co-localize with vimentin and 
actin. WFA’s potent dominant-negative effect on F-actin 
requires vimentin expression and induces apoptosis. Finally, 
WFA inhibits capillary growth in a mouse model of corneal 
neovascularization, but this drug-induced inhibition is com 
promised in vimentin de?cient mice. Thus, WFA is useful for 
incorporation as a novel chemical genetic probe of vimentin 
functions, and illuminates a potential new molecular target 
for withanolide-based therapeutics for treating angioprolif 
erative and malignant diseases, and as a model for IF protein 
related human dystrophies. 
The prototypic withanolide WFA (FIG. 1a), which is abun 
dant in the Indian medicinal plant Wilhania somnifera, is a 
potent inhibitor of angio genesis and tumor growth. To under 
stand the mode of action of this natural product, a chemical 
genetic approach was exploited that affords isolation of small 
molecule binding target(s) in accordance with Crews, C. M. 
& Splittgerber, U. Chemical genetics: exploring and control 
ling cellular processes with chemical probes, Trends Bio 
chem. Sci. 24, 317-320 (1999); Schreiber, S. L., Chemical 
genetics resulting from a passion for synthetic organic chem 
istry, Bioorg. Med. Chem. 6, 1127-1152 (1998), both herein 
incorporated by reference. Towards this end, a novel WFA 
biotin analog, WFA-B, was synthesized, as shown below. 
Glycine 
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To generate the WFA-biotinylated analog, the C2_7 
hydroxyl group of WFA was ?rst derivatized with glycine, 
which introduced a free amine functional group for subse 
quent biotin coupling. The amine group was coupled with a 
biotinylated 12-hydrocarbon chain linker to produce WFA 
Gly-LC-LC-biotin (hereinafter “WFA-B”), as taught by 
Yokota,Y., Bargagna-Mohan, P., Ravindranath, P. P., Kim, K. 
B. & Mohan, R., Development of Withaferin A analogs as 
probes of angiogenesis, Bioorg. Med. Chem. Len. 16, 2603 
2607 (2006), herein incorporated by reference. 
WFA-B binds to a 56 kDa protein that is irreversibly tar 
geted by WFA in vivo in human umbilical vein endothelial 
cells (HUVECs). To isolate this WFA-target, bovine aortic 
endothelial cells (BAECs) were treated with WFA-B, and 
biotinylated proteins were af?nity-puri?ed over NEUTRA 
VIDINTM columns and fractionated by gel electrophoresis. 
Gels stained with Coomassie blue dye con?rmed the isolation 
of this 56 kDa protein (FIG. 1b). 
Af?nity isolation of WFA-B-binding proteins was con 
ducted as follows. BAECs were preincubated with DMSO 
(Veh) or with 5 uM WFA for 30 minutes and subsequently 
with 5 uM WFA-B for 2 hours. Cell lysates prepared in 1% 
Triton X-100 buffer were puri?ed over NEUTRAVIDINTM 
a?inity columns and subjected to SDS-PAGE. The gel was 
stained with Coomassie blue. The arrow points to the 56 kDa 
protein band and asterisks mark the co-eluted 51 kDa and 43 
kDa proteins. 
LC-MS/MS characterization of this protein identi?ed the 
56 kDa protein as vimentin (27% protein coverage), an IF 
protein that is abundant in mesenchymal cells. To further 
support that vimentin is bound by WFA-B in vivo, HUVECs 
were treated with WFA-B in the presence and absence of 
unconjugated WFA, and total cellular lysates were gel-frac 
tionated and protein blots probed with streptavidin-HRP. 
Referring to FIG. lc, the blot con?rms that WFA-B binds to 
the 56 kDa protein in HUVECs. This experiment was con 
ducted using cells preincubated with DMSO or WFA for 30 
minutes and subsequently with WFA-B for 2 hours. Soluble 
proteins extracted in 1% Triton X-100 were fractionated by 
SDS-PAGE and blotted. This blot, as well as those of FIGS. 
1d and 1e, were developed with Streptavidin-HRP. Biotin 








As shown in the blot of FIG. 1d, WFA-B binds vimentin in 
HUVECs. The blot of FIG. 1d was produced using cell cul 
tures preincubated with DMSO (Veh) or with 5 uM WFA or 1 
uM (WFA*) for 30 minutes and subsequently with 5 uM 
WFA-B for 2 hours. Cell lysates prepared in 1% Triton X-100 
buffer were puri?ed over NEUTRAVIDINTM a?inity col 
umns and subjected to SDS-PAGE and western blotted with 
antivimentin V9 antibody. 
Referring now to FIG. 1e, in vitro ligand binding assays 
were performed which show that vimentin is bound by 
WFA-B in a WFA-competitive manner. The assays were per 
formed using soluble hamster vimentin incubated with dif 
ferent doses of WFA or inactive congener 12-D WS for 1 hour 
and subsequently with either 0.3 or 1 uM WFA-B for 1 hour. 
The proteins were fractionated by SDS-PAGE, blotted and 
biotinylated adduct was detected by streptaviding-HRP with 
chemiluminescence. 
The WFA-B-a?inity chromatographic approach (FIG. 1b) 
also led to co-isolation of 51 kDa [3-tubulin and 43 kDa 
[3-actin. Since vimentin has been reported to interact with 
actin and it is a cargo for microtubule-dependent transport, it 
is not unexpected that actin and tubulin would co-isolate with 
WFA-B-modi?ed vimentin. 
Next, to identify the amino acid residue(s) of vimentin 
covalently modi?ed by WFA, puri?ed hamster vimentin was 
incubated with WFA and the protein-ligand complexes sub 
jected to tryptic digestion and LC-MS/ MS analysis. A search 
for the position of adduct formation (a molecular mass shift of 
470) in the tryptic fragments of vimentin revealed that the 
sole cysteine residue at position 327 (position 328 in human 
vimentin) in the (x-helical coil coiled 2B rod domain of 
vimentin is uniquely modi?ed by WFA (data now shown). A 
three-dimensional model of the WFA-vimentin complex was 
developed using x-ray crystal structures of vimentin and 
WFA. Molecular modeling studies revealed a stable binding 
mode for WFA in the surface binding pocket of tetrameric 
vimentin between the pair of head-to-tail (x-helical dimers 
(FIG. 2a). In this simulated model, the C3 and C6 carbons of 
WFA lie in close proximity to the cysteine residue in the 
vimentin A-helix (FIG. 2b), permitting a nucleophilic attack 
by this thiol group on the electrophilic carbon centers (FIG. 
20). Remarkably, the amino acid residues of vimentin 
(Gln324, Cys328 and Asp 331) that make contact with WFA 
(FIG. 20) are identical from ?sh to mammals, as shown in the 
table below. 
Sequence 
Species Sequence Listing Identifier 
Human: RQAKQES TEYRRQVQALTCEVDS LKGTNESLERQMREMEEN SEQ ID NO: 1 
Chimp anz ee : RQAKQES TEYRRQVQAPTCEVDS LKGTNESLERQMREMEEN SEQ ID NO: 2 
Mac aque: RQAKQESNEYRRQVQALTCEVDS LKGTNESLERQMREMEEN SEQ ID NO: 3 
A . Green monkey: RQAKQESNEYRRQVQALTCEVDS LKGTNESLERQMREMEEN SEQ ID NO: 4 
Rhe sus monkey: RQAKQESNEYRRQVQALTCEVDS LKGTNESLERQMREMEEN SEQ ID NO: 5 
P ig : RQAKQESNEYRRQVQALTCEVDS LKGTNESLERQMREMEEN SEQ ID NO: 6 
Dog : RQAKQESNEYRRQVQALTCEVDS LKGTNESLEHQMREMEEN SEQ ID NO: 7 
Bovine: RQAKQESNEYRRQVQALTCEVDS LKGTNESLERQMREMEEN SEQ ID NO: 8 
Hamst er: RQAKQESNEYRRQVQALTCEVDS LKGTNESLERQMREMEEN SEQ ID NO: 9 
Mouse : RQAKQESNEYRRQVQALTCEVDS LKGTNESLERQMREMEEN SEQ ID NO: 1 O 
Rat : RQAKQESNEYRRQVQALTCEVDS LKGTNESLERQMREMEEN SEQ ID NO: 1 l 
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— cont inued 
Sequence 
Species Sequence Listing Identifier 
Chicken: RQAKQEANEYRRQIQALTCEVDSLKGSNESLERQMREMEEN SEQ ID NO: 12 
Frog: RQAKQETSDFRRQIQALTCEVDSLKGSNESYERQMREMEEN SEQ ID NO: 13 
Fish (Trout) : RQAKQEANEYRRQVQALTCEVDSLKGTNESMERQMRELEES SEQ ID NO: 14 
As shown from the table, the binding site of WFA in vimen 
tin is evolutionarily conserved. Amino acid sequences from 
within the 2B domain of vimentins of different vertebrate 
species reveal the overall high level of sequence conservation. 
The speci?c amino acids that make contact with WFA (bold), 
as determined from our molecular modeling studies, are evo 
lutionarily identical. 
Another feature illustrated by this model is that the orien 
tation of C27 hydroxyl group places it outside the binding 
cleft; thus, biotinylated WFA is able to retain the ?exibility to 
bind immobilized NEUTRAVIDINTM after modifying tet 
rameric vimentin. On the other hand, the simulated model of 
vimentin/the inactive congener 12-D WS (FIG. 2d) reveals 
that steric hindrances from the C5 alpha-hydroxyl and the 
C6-C7 epoxide of WFA are likely to prevent such a nucleo 
philic attack by the reactive thiol group on 12-D WS. This 
distinction between these two withanolides in their binding 
modes with vimentin is further corroborated by comparing 
the molecular docking-simulated internuclear distances 
between WFA and 12-D WS with vimentin, and this data is 
consistent with lack of in vitro binding activity of 12-D WS to 
vimentin (FIG. 1d) and the absence of its endothelial cell 
targeting activity. 
The clinical importance of the cysteine residue in vimentin 
lies in its propensity for being preferentially oxidized in 
vimentin compared to other cyto skeletal proteins from rheu 
matoid arthritis patients. Because this unique cysteine residue 
under oxidizing conditions can participate in disul?de cross 
linking between a pair of vimentin dimers leading to disrup 
tion to the ?lament structure in vitro, how chemical modi? 
cation of cysteine by WFA affects the vimentin 1F structure 
was investigated. Employing soluble tetrameric vimentin in 
?lament polymerization assays in vitro, although WFA at 
high doses does not block ?lament assembly per se, the drug 
induces formation of ?lamentous aggregates, many of which 
display amorphous condensed structures as revealed in nega 
tively stained transmission electron micrographs (FIGS. 
3a-3 
FIG. 3a depicts tetrameric soluble hamster vimentin poly 
merized in the presence of 170 mM NaCl by incubation at 370 
C. for 1 hour. The protein was ?xed with 0.5% glutaralde 
hyde, stained with uranyl acetate and observed by transmis 
sion electron microscopy. The presence of vehicle solvent 
does not interfere with ?lament formation. 
FIG. 3b depicts polymerization of tetrameric vimentin in 
the presence of 25 uM WFA, which produces extensive ?la 
mentous aggregates, and FIG. 30 depicts many irregular frag 
mented aggregated structures.As shown in FIG. 3d, 12-D WS 
(25 uM) does not disrupt vimentin polymerization. 
BAECs treated with DMSO (FIGS. 3e, 3g, 31') or 3 uM 
WFA (FIGS. 3], 3h, 3j) for 18 hours were stained for vimentin 
using a monoclonal anti-vimentin antibody (green) and co 
stained with phalloidin-rhodamine (red). The vimentin 
(FIGS. 3e, 3]) and phalloidin-stained images (FIGS. 3g, 3h), 
in ?uorescence overlap, reveal the presence of numerous 











and disrupted F-actin in WFA-treated cells compared to con 
trols (FIGS. 31', 3j). FIG. 3k is a western blot analysis of 
HUVECs which shows dose-responsive increases in vimen 
tin cleavage products (arrows) with WFA treatment after 2 
hours, as detected with the monoclonal anti-vimentin V9 
antibody. FIG. 3l depicts higher concentrations and longer 
periods of exposure to WFA (4 hours) cause reduction in 
levels of the 56 kDa protein (asterisk) and increased abun 
dance of cleavage products of vimentin (arrows). 
The amorphous condensed structure phenotype is not 
observed with lower doses of WFA or equivalent high dose of 
the inactive congener 12-D WS. To further corroborate that 
vimentin aggregation by WFA treatment is associated with 
perturbation of the cytoskeleton structure, the drug effects in 
BAECs were investigated by immunostaining. Cells treated 
with 3 uM WFA showed condensation of vimentin ?laments 
around the perinuclear region and the presence of numerous, 
vimentin-positive staining particles in the cytoplasm (com 
pare FIG. 3e with FIG. 3]). lmportantly, these vimentin par 
ticulates strongly co-stain for actin (compare FIG. 3h with 
FIG. 3 j), exemplifying the role of the WFA-binding domain in 
control of cytoskeletal structure through the actin-binding 
activity of vimentin 2B domain. 
As it became apparent that vimentin targeting by WFA may 
initiate signaling events leading to cellular apoptosis, the 
effect of WFA on soluble tetrameric vimentin was investi 
gated. Using western blot analysis of soluble proteins from 
HUVECs treated with WFA, dose-dependent (above 2 uM) 
increases in vimentin cleavage products became detectable 
by 2 hours after drug treatment (FIGS. 3k and 3!). Addition 
ally, two-dimensional-westem blot analysis reveals that 
WFA-B also causes several full-length (~53-56 kDa) iso 
forms of vimentin to disappear in a manner similar to WFA 
induced effects in HUVECs (data not shown), data that fur 
ther supports the in vivo drug-mimetic effect of this WFA 
analog. 
Since IF protein aggregation has been shown to negatively 
impact the ubiquitin proteasome pathway (U PP) resulting in 
proteasome inhibition, an investigation as to whether the 
UPP-targeting activity of WFA is also regulated in a vimen 
tin-dependent manner was undertaken. Employing the widely 
used MCF-7 vimentin-de?cient model of Bar, H. et al., 
Forced expression of desmin and desmin mutants in cultured 
cells: impact of myopathic missense mutations in the central 
coiled-coil domain on network formation, Exp. Cell. Res. 
312, 1554-1565 (2006), herein incorporated by reference, it 
was determined that co-treatment with WFA increases levels 
of polyubiquitinated proteins in vimentin transfected MCF -7 
cells, but not in the vector controls (FIG. 4a). MCF-7 cells 
that lack endogenous 1F proteins were transfected with 
human vimentin cDNA or a vector control and after 24 hours 
cells were treated with either vehicle or 2 uM WFA for 1 hour. 
Cell lysates were prepared and equal amounts of protein 
subjected to SDS-PAGE and protein blots probed with anti 
ubiquitin antibody. Blots were re-probed with anti-GAPDH 
antibody. 
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Referring to FIG. 4b, 20S proteasome (bovine) preparation 
was incubated with vehicle (Con), 0.5 uM, 1.0 HM and 10 uM 
WFA or with 10 nM Epoxomicin (pr) in the presence of 
LLVY-AMC substrate at room temperature. Fluorescence 
readings from triplicate samples were obtained at different 
time intervals from the 96-well plate using excitation at 355 
nm and emission at 430 nm. The release of product was 
plotted against time for each concentration of inhibitor. 
Referring to FIG. 40, embryonic ?broblast cell lines 
derived from vimentin-de?cient mice and wild-type litter 
mates were treated with vehicle or 5 uM WFA for 24 hours. 
Cells were harvested and stained with annexin V-FITC and 
propidium iodide and extent of apoptosis assessed by ?ow 
cytometry. The fold-apoptotis for drug over vehicle-treated 
samples for each cell line was plotted (n:2 experiments). 
Referring to FIG. 4d, BAECs were transduced with WFA 
treated vimentin and cells were stained after 18 hours. Cells 
transduced with WFA-modi?ed vimentin show condensed 
vimentin ?laments localized largely in and around the 
nucleus and the presence of vimentin-staining particulates 
(FIG. 4e). Cells transduced with vehicle-treated vimentin 
show well distributed orchestration of vimentin IFs (FIG. 4]) 
and actin cytoskeleton (FIG. 4g). Results representative of 
n:3 experiments are shown. 
Referring back to FIG. 4a, to corroborate that vimentin 
targeting and not the possible direct inhibition of the 20S 
proteasome by WFA mediates its UPP-targeting function, 
tests were conducted on WFA in proteasome kinetic assays. 
Whereas epoxomicin, a highly selective proteasome inhibi 
tor, signi?cantly inhibits the 20S proteasome’s major cata 
lytic function at 10 nM, WFA, even at cytotoxic concentra 
tions of 10 uM, minimally inhibits this catalytic activity (FIG. 
4b). The Kobs/ [I] (M_1S_l), a measure of the ef?ciency of 
inactivation, was calculated to be 340180 (0.5-10 uM) for 
WFA, while that ofepoxomicin is 44,5 1017,000 (10-75 nM). 
Contrary to a recent report of Yang, H., Shi, G. & Dou, Q. P., 
The tumor proteasome is a primary target for the natural 
anticancer compound Withaferin A isolated from “Indian 
Winter Cherry,” Mol. Pharmacol. November 8 online (2006), 
herein incorporated by reference, the presently acquired data 
provides evidence that WFA-modi?ed vimentin may mediate 
sequestration of ubiquitinated proteins and result in protea 
some inhibition in vivo. Thus, employing cell lines derived 
from vimentin-de?cient and isogenic wild-type mouse 
strains confers enhanced resistance to drug-induced apopto 
sis with wild-type cells having a 7-fold greater rate of apop 
tosis (FIG. 40). Furthermore, exploiting a protein transduc 
tion methodology to introduce the WFA-modi?ed, dominant 
negative, vimentin tetramers into cells, immunostaining 
demonstrates that endogenous vimentin IFs and F-actin are 
found to aggregate, whereas cells transduced with vehicle 
treated vimentin do not produce this phenotype (compare 
FIG. 4d with FIG. 4]). Collectively, these ?ndings demon 
strate that vimentin-targeting by WFA can affect the severe 
alterations in the cytoskeleton architecture (FIGS. 4e and 4g). 
Since WFA exerts potent angiogenesis inhibitory activity 
in vivo, drug activity on de novo capillary growth in vimentin 
de?ciency was investigated. The mouse model of injury 
induced corneal neovascularization shows that WFA mark 
edly suppresses neovascularization in wild-type mice (73% 
inhibition, n:8; P:0.002), whereas it only marginally attenu 
ates neovascularization in vimentin-null mice (29% inhibi 
tion; n:10; P:0.005) (FIG. 5), revealing that inhibition of 
capillary growth by WFA is mediated predominantly by 
vimentin. Interestingly, the vascularization response of 












mice, which is consistent with previous reports on impaired 
angiogenesis in vimentin de?ciency. 
WFA has been recently shown to bind annexin II in cancer 
cell lines, as shown by Falsey, R. R. et al., Actin micro?lament 
aggregation induced by WithaferinA is mediated by annexin 
II, Nat. Chem. Biol. 2, 33-38 (2006), herein incorporated by 
reference. However, this 36 kDa protein is not detected in in 
vivo WFA-af?nity puri?ed proteins from human or bovine 
endothelial cells (FIG. 1b), nor was it detected by western 
blotting of NEUTRAVIDINTM-puri?ed proteins in our stud 
ies (data not shown). Thus, differences in the construction of 
the biotinylated WFA analogs (e.g., inclusion of a long, linear 
hydrocarbon linker between the natural product and biotin), 
or their applications for target isolation (in vitro versus in vivo 
labeling), could account for different targets being bound to 
WFA. It is also possible that WFA has context-related, bind 
ing speci?cities for different targets in vivo, a speculation that 
will need to be rigorously tested. 
Vimentin is the primary target of WFA in vivo, and this 
small molecule can perturb vimentin function. Use of a small 
molecule to inhibit vimentin function can serve as a comple 
mentary approach to classical genetic studies of disorders of 
IFs, shown in Bar, H., Strelkov, S. V., Sjoberg, G., Aebi, U. & 
Herrrnann, H., The biology of desmin ?laments: how do 
mutations affect their structure, assembly, and organi sation?, 
J. Slrucl. Biol. 148, 137-152 (2004), herein incorporated by 
reference. Thus, WFA and derivative steroidal-lactones rep 
resent a useful chemical genetic tool for studies of the type-III 
IF proteins. As vimentin modulates the immune response and 
is overexpressed in prostate and other cancers, WFA holds 
great promise as a potential lead for the development of small 
molecule therapeutics. 
Based on the foregoing experiments and test results, there 
are many potential applications for development of small 
molecule based probes and analogs. For example, the binding 
of the WFA probe can be used to modulate vimentin protein 
function and, thus, the binding pocket can serve as a novel 
target for the development of small molecule agonists or 
antagonists of vimentin function. In another use, one can 
monitor intracellular transport and localization of vimentin 
protein to different subcellular locations in vivo by conjugat 
ing a detection label, such as a ?uorescent tag, radiolabel or 
biotin, to WFA. Since these probes bind selectively and 
covalently to vimentin, they allow one to follow this marker in 
a whole range of known tissues from a variety of proliferative 
diseases, such as cancer, arthritis, diabetes, etc., serving 
essentially as a sensitive diagnostic tool. 
In another use, WFA-based analogs can be employed to 
more potently modify vimentin function and thereby generate 
new classes of pharmacological drugs for treatment of human 
diseases. In addition, the WFA-vimentin binding site infor 
mation could be employed to probe similar binding sites in 
other IF proteins, for which the cysteine group is known to be 
present in a similar coiled coil domain of the IFs. 
The following experimental conditions provide additional 
background and details regarding the aforementioned experi 
ments, which support the present screening method as an 
effective method for identifying potential small molecule 
drugs and their respective binding sites. 
All cell culture supplies were purchased from Gibco unless 
otherwise speci?ed. Antibodies were from Santasz Bio 
technology unless otherwise speci?ed. WFA and l2-D WS 
were obtained from Chromadex and stock solutions were 
freshly prepared in DMSO. All cell reagents were purchased 
from Invitrogen. 
HUVECs and BAECs cells were obtained from Cascade 
Biologicals and cultured according to vendor’s protocols. 
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MCF-7 breast cancer cell line was obtained from ATCC and 
cultured in RPMI 1640 medium containing 10% Fetal Bovine 
Serum (FBS). MFT-16 cells from embryo ?broblasts of 
vimentin homozygous-de?cient mice (Vim_/_) and MFT-6 
cells from embryo ?broblasts of wild-type (Vim+/+) mice 
were obtained from Robert Evans (University of Colorado, 
Denver) and cultured in F12:DMEM (1:1) medium supple 
mented with 5% FBS. All cells were cultured in humidi?ed 
incubators at 370 C.-5% CO2 conditions. 
Isolation of WFA-B-Binding Proteins by Af?nity Chroma 
tography. 
The synthesis and chemical characterization of WFA-B, 
demonstration of its biological activity in endothelial cells, 
and use to identify biotinylated proteins from HUVECs was 
previously reported (Yokota 2006). For scale-up studies, 
BAECs were pre-incubated with DMSO or 5 uM WFA for 1 
hour and subsequently treated with 5 uM WFA-B for 2 hours. 
Cells were washed in ice-cold phosphate buffered saline 
(PBS) and cytoplasmic extracts were prepared in BufferA (5 
mM Tris, pH 7.6, 50 mM NaF, 1% Triton X-100, 5 mM 
EGTA), supplemented with a proteinase inhibitor cocktail 
(Roche). After centrifugation, equal amounts of protein were 
pre-cleared on agarose beads (Sigma) to remove non-speci?c 
agarose-binding proteins. The beads were centrifuged and 
pre-cleared cell lysates were repeatedly loaded three times on 
columns containing NEUTRAVIDINTM-agarose beads 
(Pierce) to maximize immobilization of biotinylated proteins. 
After extensive washing with ice-cold Buffer A, bound bioti 
nylated proteins were eluted in Laemeli gel loading buffer 
containing [3-mercaptoethanol and fractioned by SDS-PAGE 
on 15x15 cm gels. Gels were stained with Coomassie blue 
dye and bands corresponding to 56 kDa, 51 kDa and 43 kDa 
protein were excised for mass spectrometric analysis. 
Identi?cation of Af?nity Puri?ed Proteins by LC-MS/ MS. 
All mass spectra reported in this disclosure were acquired 
by the University of Kentucky Mass Spectrometry Facility. 
Gel pieces were digested with trypsin, and LC/MS/MS spec 
tra were acquired on a ThermoFinnigan LCQ “Classic” qua 
drupole ion trap mass spectrometer (Finnigan Co., San Jose, 
Calif.). Separations were performed with an HP 1100 high 
performance liquid chromatograph modi?ed with a custom 
splitter to deliver 4 ul/min to a custom C18 capillary column 
(300 um inner diameter><15 cm). Gradient separations con 
sisted of a 2-minute isocratic step at 95% water and 5% 
acetonitrile (both phases contain 0.1% formic acid). The 
organic phase was increased to 20% acetonitrile over 8 min 
utes and then increased to 90% acetonitrile over 25 minutes; 
held at 90% acetonitrile for 8 minutes and then increased to 
95% in 2 minutes; ?nally they were returned to the initial 
conditions in 10 minutes (total acquisition time 45 minutes 
with a 10 minute recycle time). Tandem mass spectra were 
acquired in a data-dependent manner. Three micro scans were 
averaged to generate the data-dependent full-scan spectrum. 
The most intense ion was subjected to tandem mass spectrom 
etry, and three microscans were averaged to produce the 
MS/ MS spectrum. Masses subjected to the MS/ MS scan were 
placed on an exclusion list for 2 minutes. Resulting MS-MS 
spectra were searched against mammalian proteins in the 
Swiss-Prot database using the Mascot search engine (Matrix 
Science). 
3D Model of the Human Vimentin Fragment. 
The initial coordinates of 2B human vimentin fragment 
used in our computational studies came from the X-ray crys 
tal structure (pdb code: 1gk4.pdb) deposited in the Protein 
Data Bank. To encompass the structure of the protein envi 
ronment surrounding the active residue Cys328, the missing 












and B helices) were built using the (x-helical template struc 
ture and the automated homology modeling tool Modeler/ 
InsightII software (Accelrys, Inc.). Then, the best 3D model 
was solvated in water and re?ned by performing a long-time 
molecular dynamics (MD) simulation in water. 
Molecular Docking. 
To explore the possible vimentin-ligand binding mode, the 
?rst step was to dock the ligand, i.e. WFA or 12-D WS, to 
vimentin tetramer fragment by virtue of their geometric 
complementarity. The molecular docking for each vimentin 
ligand binding was carried out in the same way as previously 
done when studying other protein-ligand binding systems, as 
disclosed in Hamza, A. & Zhan, C.-G., How Can (—)-Epigal 
locatechin Gallate from Green Tea Prevent HIV-1 Infection? 
Mechanistic Insights from Computational Modeling and the 
Implication for Rational Design of Anti-HIV-l Entry Inhibi 
tors, J. Phys. Chem. B 110, 2910-2917 (2006), herein incor 
porated by reference. 
A ligand-binding site was de?ned as that consisting of the 
residues within a sphere (with a radius of 20 A) centered at 
Cys328 residue. The ligand was initially positioned at ~10 A 
in front of Cys328 of the binding site. The initial docking 
calculations were performed on the ligand with the vimentin 
fragment binding site using the ‘automatic docking’ Af?nity 
module of the InsightII package (Accelrys, Inc.). The Af?nity 
methodology uses a combination of Monte Carlo type and 
simulated Annealing procedures to dock the guest molecule 
(the ligand) to the host (the receptor). The vimentin-ligand 
binding structure obtained from the initial docking was fur 
ther re?ned by performing an MD simulation in a water bath. 
Western Blotting Experiments. 
After treatments, cells were washed in PBS and extracts 
having equal amounts of proteins were subjected to SDS 
PAGE on 4-20% Tris-glycine gels (BioEpress) and trans 
ferred to Immun-Blot PVDF membrane (Bio-Rad) using 
standard techniques. Primary antibodies were diluted in 5% 
non-fat dry milk Tris buffered saline, 0.02% Tween-20 
(N FDM-TBST) at the concentration of 1:500, and secondary 
antibodies were used at 1:1000 dilution. Blots were exten 
sively washed in TBST buffer and developed using enhanced 
chemiluminescence method (Amersham) and exposed to 
x-ray ?lm. 
Transfection Studies. 
MCF-7 cells were transfected with a pCMV6-XL5 vector 
containing the human vimentin cDNA under CMV promoter 
according to vendor instructions (Origene). Control samples 
were transfected with an empty vector (PCMV6-XL4). 
Transfected cells were allowed to recover for 12 hours and 
subsequently treated with 2 uM WFA for 18 hours. Equal 
amounts of protein lysates were then subjected to western 
blotting and probed with mouse monoclonal antibody against 
ubiquitin proteins. 
Protein Transduction Studies. 
Tetrameric vimentin (0.5 pg) (Cytoskeleton) was incu 
bated with 10 uM WFA or an equivalent amount of vehicle 
(DMSO) for 1 hour at 37° C. to form protein-WFA adducts. 
Vimentin-WFA or vimentin alone (0.5 pg) were mixed with 
the CHARIOTTM protein transduction reagent (Active Motif) 
and incubated for 30 minutes at 24° C. to form complex 
according to instructions of manufacturer. The protein 
CHARIOTTM complex was subsequently added to BAECs in 
serum-free medium and incubated for 1 hour at 370 C.-5% 
CO2 conditions. Fresh complete medium was then added and 
cells were incubated for an additional 18 hours under normal 
culture conditions. Cells were processed for immunohis 
tochemistry analysis, as described. 
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Apoptosis by Flow Cytometry. 
To assess the apoptosis activity of WFA, embryonic ?bro 
blast vimentin-de?cient cell lines (V1m_/_; MFT-16) and 
wild-type (V1m+/+; MFT-6) cells were treated with 5 uM WFA 
or an equivalent amount of vehicle (DMSO) for 24 hours at 
37° C.-5% CO2 conditions in complete medium. Apoptotic 
cells were measured by using the VYBRANTTM Apoptosis 
Assay Kit (Molecular Probes) according to the manufactur 
er’s instructions. Flow cytometric analysis was conducted at 
the University of Kentucky Core Flow Cytometry Center. 
Cell Staining Procedures and Fluorescence Imaging. 
After treatments, BAECs were washed with PBS and ?xed 
with 4% paraformaldehyde for 5 minutes. Cells were then 
permeabilized with 0.1% Triton-X in PBS for 20 minutes at 
4° C. and blocked for 30 minutes in 3% BSA to prevent 
nonspeci?c binding. Rabbit polyclonal vimentin antibody 
(Vim) or mouse monoclonal vimentin antibody (V9) was 
applied to cells for 1 hour at 24° C. at 1:400 dilution in PBS. 
After extensive washes with PBS, cells were incubated with 
anti-rabbit FITC-conjugated secondary antibody (1:500) or 
anti-mouse Texas Red-conjugated secondary antibody 
(1:500) for 30 minutes. After washing three times with PBS, 
cells labeled with Vim-antibody were incubated with phalloi 
din conjugated to Rhodamine (1:200) for 20 minutes. After 
extensive washes (1-2 hours), cells were visualized using a 
Nikon TE2000 microscope. 
Transmission Electron Microscopy of Vimentin Filaments. 
Tetrameric hamster vimentin was subjected to in vitro ?la 
ment formation assays using vendor-supplied reagents and 
instructions (Vimentin Filament Biochemistry Kit, Denver, 
Colo.). Vimentin (0.5 mg/ml) was mixed with WFA (5 uM or 
25 uM), DMSO or 12D-WS (25 uM) in ?lament polymeriza 
tion buffer (170 mM NaCl ?nal concentration) and incubated 
for 1 hour at 37° C. Protein was immediately ?xed in 0.5% 
glutarldehyde and stained with uranyl acetate and applied to 
copper grids for EM staining (University of Kentucky Core 
Microscopy and Imaging Facilities). Over 100 grids for each 
treatment were viewed at 80 kV on a FEI Biotwin 12 trans 
mission electron microscope and 25 representative images 
were collected. The experiment was repeated in entirety. 
Enzyme Kinetic Studies. 
kaSSOCZ-a?on values were determined as follows. Inhibitors 
were mixed with a ?uorogenic peptide substrate and assay 
buffer (20 mM Tris (pH 8.0), 0.5 mM EDTA, and 0.035% 
SDS) in a 96-well plate. The chymotrypsin-like activity was 
assayed using the ?uorogenic peptide substrates Suc-Leu 
Leu-Val-Tyr-AMC (Sigma-Aldrich). Hydrolysis was initi 
ated by the addition of bovine 20S proteasome, and the reac 
tion was followed by ?uorescence (360-nm excitation/460 
nm detection) using a Microplate Fluorescence Reader 
(FL600; Bio-Tek Instruments, Inc., Winnoski, Vt.) employ 
ing the software KC4 v.2.5 (Bio-Tek Instruments, Inc., 
Winooski, Vt.). Reactions were allowed to proceed for 60-90 
minutes, and ?uorescence data were collected every 1 minute. 
Fluorescence was quanti?ed as arbitrary units and progres 
sion curves were plotted for each reaction as a function of 








gram by nonlinear least squares ?t of the data to the following 
equation: ?uorescenceq/SH [(vO —vS)/k0bse,ved] [1 —exp (—k0bi 
served t)], where v0 and vs are the initial and ?nal velocities, 
respectively, and kobserved is the reaction rate constant. The 
range of inhibitor concentrations tested was chosen so that 
several half-lives could be observed during the course of the 
measurement. Reactions were performed using inhibitor con 
centrations that were <100-fold of those of the proteasome 
assayed. 
Corneal Neovascularization Assays in Mice. 
Vimentin homozygous-de?cient mice (vim_/_) and vimen 
tin-heterozygous-de?cient mice (vim+/_) in the 129/Svev 
background were obtained from David Markovitz (Univer 
sity of Michigan Medical Center) and breeding colonies 
established at the University of Kentucky. All mice were 
housed in speci?c pathogen-free cages in designated lab ani 
mal housing facilities. Age-matched littermates were geno 
typed by polymerase chain reaction, as described, and vim_/_ 
and vim+/+ mice were employed for corneal vascularization 
experiments. In brief, mice between 4-6 weeks of age were 
anesthetized by intraperiteoneal injection (i.p.) of ketamine 
and xylazine. Corneas were topically anesthetized by appli 
cation of proparacain drop and 1 microliter drop of dilute 0.1 
M sodium hydroxide was applied for 1 minute. The cornea 
was immediately washed extensively in saline solution and 
corneal and limbal epithelium gently removed by scraping 
with a blunt Tooke corneal knife. The cornea was topically 
treated with Atropine eye drop and covered with tobramycin 
and erythromycin antibiotic eye ointment. Upon recovery 
from anesthesia, mice were replaced in cages and monitored 
by trained personnel for resumption of normal activity. WFA 
(2 mg/kg solubilized in DMSO) or vehicle (DMSO) was 
injected intraperiteoneally in some groups of mice after their 
recovery from corneal injury, and subsequently every day 
after for a period of 10 days. Mice were humanely sacri?ced 
and eyes enucleated. Mouse eyes were washed in PBS and 
dissected in half to obtain anterior segment half. The scleral 
tissue was carefully removed and corneal buttons were pre 
pared. Corneal tissues were ?xed in 100% acetone for 20 
minutes, washed in PBS for 1 hour and blocked for 18 hours 
in 1% BSA-PBS at 4° C. Cornea whole mount staining was 
performed by incubating tissues in FITC-conjugated rat anti 
mouse CD31 antibody (BD Pharmingen; 1:333 dilution in 
1% BSA-PBS) for 12 hours. Excess stain was washed away 
by incubation for 24 hours at 4° C. in 1% BSA-PBS. Corneal 
whole mounts were a?ixed to glass slides, cover-slipped and 
photographed on a Nikon TE2000 microscope. Fluorescence 
was quanti?ed by importing images in NIH Image], as taught 
by Ambati, B. K. et al., Sustained inhibition of corneal 
neovascularization by genetic ablation of CCR5, Invest. 
Oplhalmol. st. Sci. 44, 590-593 (2003), hereinafter incorpo 
rated by reference. 
Although the invention has been described in considerable 
detail with respect to preferred embodiments, it will be appar 
ent that the invention is capable of numerous modi?cations 
and variations, apparent to those skilled in the art, without 
departing from the spirit and scope of the claims. 
SEQUENCE LISTING 
<l60> NUMBER OF SEQ ID NOS: l4 
<210> SEQ ID NO 1 
<211> LENGTH: 41 
<212> TYPE: PRT 
<213> ORGANISM: Homo sapiens 





